Videos

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

This segment focuses on assessing bleeding and variceal risk before initiating anti-VEGF therapy with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee review the key efficacy and safety findings from the phase 3 MonumenTAL-3 study in relapsed/refractory multiple myeloma (RRMM).

The panel discusses long-term survival and quality of life with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee discuss the clinical rationale behind the phase 3 MonumenTAL-3 study and its role in confirming the benefit-risk profile of talquetamab in relapsed/refractory multiple myeloma (RRMM).

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Jonathan Lee, MD, MSc, and Chinmay Jani, MD, have a candid conversation about what medical training actually feels like.

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.

Sivraj Muralikrishnan, MD, analyzed HARMONi-6 safety findings for ivonescimab in NSCLC, addressing VEGF-related toxicities and global generalizability.

Education and reinforcement may improve luspatercept dose titration and persistence in community practice.

Experts weigh CML PCR milestones, urging context over rigid cutoffs when switching TKIs—and keeping treatment‑free remission goals in sight.

Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed sequencing options like luspatercept after ESA failure in RS-negative lower-risk MDS.

Dr. Lipsky addresses the framework for interpreting real-world data and cross-trial comparisons in the absence of head-to-head trials.

Clinicians weigh earlier T‑DXd use in breast cancer by preventing nausea, managing fatigue via dose reductions, and closely monitoring ILD risk in curative settings.

Experts discuss evolving care for HER2-positive metastatic breast cancer brain metastases, highlighting CNS-active drugs, earlier MRI screening, and smarter treatment decisions.

Dr. Lipsky outlines MRD testing utility across the three major treatment approaches.

Imetelstat may be considered as a frontline option for patients with a high transfusion burden, said Amer Zeidan, MBBS, MD.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss using CELMoDs to debulk tumor or restore T-cell fitness between T-cell–redirecting therapies in relapsed/refractory multiple myeloma.

Dr. Binod Dhakal leads a discussion on the increasingly complex treatment landscape of relapsed/refractory multiple myeloma (RRMM), focusing on how clinicians navigate sequencing decisions among BCMA-directed therapies, including CAR T-cell therapy and bispecific antibodies.

The TOP trial, a phase three study focused exclusively on TP53-mutant EGFR-mutant non-small cell lung cancer, validated the FLAURA2 findings in this high-risk subset, showing a striking PFS benefit of 34.0 versus 15.6 months (HR 0.44) for osimertinib plus chemotherapy over monotherapy, with a favorable duration of response of 32.7 versus 15.9 months, though overall survival data remain immature.

Dr. Park addresses management of low-grade immune-related adverse events (irAEs), the most common toxicities encountered with checkpoint inhibitors, including dermatitis, pruritus, and GI symptoms.

Dr. Ajai Chari and NP Samantha Shenoy discuss practical considerations for long-term management of newly diagnosed multiple myeloma (NDMM), focusing on treatment duration, ongoing therapy, and patient-centered care. The faculty explore the rationale for continuous treatment approaches and how response depth, including minimal residual disease (MRD) negativity, may continue to evolve with extended therapy. The conversation emphasizes that treatment duration decisions should be individualized based on tolerability, patient preferences, comorbidities, and long-term management goals. Dr. Chari and NP Shenoy also review real-world follow-up strategies, highlighting the importance of multidisciplinary collaboration, symptom management, patient education, and shared decision-making throughout the treatment journey. Practical insights are provided regarding the role of advanced practice providers in supporting adherence, monitoring treatment-related toxicities, and helping patients navigate prolonged therapy while maintaining quality of life and optimizing clinical outcomes in NDMM.

Dr. Hamid presents a 71-year-old male smoker with coronary artery disease and a 3.5 cm cervical CSCC lesion that has recurred after multiple surgical resections and adjuvant radiation therapy.

Dr. Iyengar addresses common patient fears about vision loss, noting this represents a primary concern when discussing ocular toxicity. Dr. Sunshine provides reassurance that these represent reversible changes with appropriate monitoring and early intervention, emphasizing the importance of early detection through regular examinations.

The FLAURA2 phase three trial demonstrated that adding platinum-based chemotherapy to osimertinib significantly improved outcomes over osimertinib monotherapy in first-line EGFR-mutant non-small cell lung cancer, with a median PFS of 29.4 versus 19.9 months and a statistically significant overall survival benefit of 47.5 versus 37.6 months.

Dr. Zager outlines a monitoring strategy for the Case 1 patient who is NED following surgery and radiation.

NP Schollenberger addresses how she interprets and communicates efficacy data to patients.

Dr. Binod Dhakal and Dr. Carol Ann Huff discuss how anti-CD38 exposure versus true anti-CD38 refractoriness influences treatment selection in relapsed/refractory multiple myeloma (RRMM).